Pfizer posts Phase 3 Elrexfio win in relapsed myeloma

Pfizer said its Phase 3 MagnetisMM-5 trial met its primary endpoint, with Elrexfio (elranatamab) showing a statistically significant and clinically meaningful improvement in progression-free survival versus daratumumab, pomalidomide, and dexamethasone in adults with relapsed or refractory multiple myeloma who had received at least one prior line of therapy. The April 29, 2026, topline update marks an important step for the BCMA-directed bispecific antibody, which is already marketed under accelerated approval in the U.S. for adults who have received at least four prior lines of therapy. Pfizer said safety in MagnetisMM-5 was consistent with Elrexfio’s known profile, with no new safety signals identified, and that the study remains ongoing to assess overall survival. (pfizer.com)

Why it matters: For oncology and specialty care teams, the result could help move elranatamab earlier in the treatment pathway if regulators accept the data as confirmatory evidence. That matters because Elrexfio’s current U.S. label still carries accelerated approval language tied to heavily pretreated patients, and continued approval may depend on verification of clinical benefit in confirmatory trials. If the full dataset holds up, practices may need to prepare for broader use of a therapy that already requires step-up dosing, monitoring for cytokine release syndrome and neurologic toxicity, infection vigilance, and REMS-related operational planning. (accessdata.fda.gov)

What to watch: Pfizer said it plans to discuss the interim results with global health authorities and submit detailed data at a future medical congress, so the next inflection points are full efficacy and safety readouts, overall survival maturity, and any regulatory filing tied to label expansion. (pfizer.com)